|1.||Czaja, Albert J: 8 articles (01/2012 - 02/2002)|
|2.||Lohse, Ansgar W: 5 articles (07/2010 - 02/2002)|
|3.||Vergani, Diego: 4 articles (04/2014 - 03/2002)|
|4.||Ballot, Eric: 4 articles (06/2012 - 09/2002)|
|5.||Johanet, Catherine: 4 articles (06/2012 - 09/2002)|
|6.||Norman, Gary L: 4 articles (01/2012 - 12/2002)|
|7.||Shums, Zakera: 4 articles (01/2012 - 12/2002)|
|8.||Herkel, Johannes: 4 articles (07/2010 - 02/2002)|
|9.||Lohse, A W: 4 articles (09/2006 - 04/2000)|
|10.||Bogdanos, Dimitrios P: 3 articles (02/2015 - 03/2002)|
04/01/2007 - "To study the significance of anti-soluble liver antigen/liver-pancreas (anti-SLA/LP) in diagnosing and typing autoimmune hepatitis (AIH). "
04/01/2007 - "[The significance of anti-soluble liver antigen/liver-pancreas in diagnosing and typing autoimmune hepatitis]."
03/01/2001 - "Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis."
01/01/2000 - ""Soluble liver antigen" (SLA) has been reported to be an infrequent but in certain cases a unique marker of autoimmune hepatitis, with cytokeratins 8 and 18 as major antigenic components. "
06/01/2015 - "Three databases PUBMED, EMBASE, and OVID were systemically searched up to January 2015 using the terms "soluble liver antigen" or "liver-pancreas antigen" and "autoimmune hepatitis" with restriction to English-language. "
|2.||Liver Diseases (Liver Disease)
12/01/2005 - "[Clinical and laboratory characteristics of anti-soluble liver antigen/liver-pancreas (SLA/LP) autoantibody positive liver disease patients]."
02/01/2013 - "Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study."
04/01/2014 - "Perinuclear anti-nuclear neutrophil antibody (p-ANNA) is an additional marker of AIH-1; anti soluble liver antigen (SLA) antibodies are specific for autoimmune liver disease, can be present in AIH-1 and AIH-2 and are associated with a more severe clinical course. "
03/01/2002 - "Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease."
11/01/1993 - "Antibodies to soluble liver antigen, P450IID6, and the E2 subunits of mitochondrial dehydrogenase complexes occur in autoimmune liver diseases, but their specificities and implications are uncertain. "
|3.||Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
01/01/1994 - "Antibodies directed against soluble liver antigen (SLA), liver kidney microsomal antigen (LKM-1-AG), and antimitochondrial antigen M2 (M2-AMA) are critical serological markers for the differential diagnosis of autoimmune chronic active hepatitis (AI-CAH) and primary biliary cirrhosis (PBC). "
07/01/1989 - "No patient developed autoantibodies specifically associated with autoimmune liver diseases such as liver kidney microsomal antibodies, autoantibodies to soluble liver antigen and the primary biliary cirrhosis specific subtypes of antimitochondrial antibodies. "
01/01/2005 - "Antibodies to soluble liver antigen/liver pancreas, asialoglycoprotein receptor, actin, liver cytosol type 1, nuclear antigens specific to primary biliary cirrhosis, and pore complex antigens constitute an investigational repertoire that promises to have prognostic and diagnostic value. "
08/01/2010 - "Antibodies to soluble liver antigen, actin, liver cytosol type 1, asialoglycoprotein receptor, chromatin, cyclic citrullinated peptide, and uridine glucuronosyltransferases have been associated with the occurrence, severity, and progression of autoimmune hepatitis, and antibodies to Sp100, gp210, and centromere have had similar implications in primary biliary cirrhosis. "
12/01/2009 - "Sera from 281 patients with chronic cholestatic conditions, including primary biliary cirrhosis (PBC), primary sclerosing cholangitis, AMA-positive autoimmune hepatitis, and "undetermined cholangiopathy" were tested for the following PBC-associated autoantibodies: anti-gp210, anti-sp100, conventional anti-M2, anti-M2 (MIT3) IgG, anti-M2 (MIT3) IgA, as well as anti-centromere, anti-soluble liver antigen, and anti-chromatin. "
|5.||Disease Susceptibility (Diathesis)
|2.||Primary sclerosing cholangitis
|5.||mycophenolate mofetil (Cellcept)
|7.||HLA-DRB1 antigen (HLA DRB1)